Valuation: Clarity Pharmaceuticals Ltd

Market Cap 1.04B 739M 640M 600M 547M 1.03B 70.49B 7.06B 2.76B 35.3B 2.77B 2.71B 118B P/E 2026 *
-9.55x
P/E 2027 * -8.78x
Enterprise Value 884M 625M 542M 508M 463M 870M 59.63B 5.97B 2.33B 29.86B 2.35B 2.3B 99.56B EV / Sales 2026 *
-
EV / Sales 2027 * 1,066x
Free-Float
79.07%
Yield 2026 *
-
Yield 2027 * -
1 day-0.36%
1 week+4.48%
Current month+18.14%
1 month+15.70%
3 months-1.75%
6 months-2.10%
Current year-17.16%
1 week 2.54
Extreme 2.54
2.96
1 month 2.03
Extreme 2.03
2.96
Current year 1.8
Extreme 1.8
4.26
1 year 1.8
Extreme 1.8
5.87
3 years 0.92
Extreme 0.92
8.98
5 years 0.36
Extreme 0.36
8.98
10 years 0.36
Extreme 0.36
8.98
Manager TitleAgeSince
Chief Executive Officer - 11/10/2024
Chief Executive Officer - 01/01/2010
Director of Finance/CFO - 04/04/2022
Director TitleAgeSince
Chairman - 01/11/2013
Director/Board Member - 01/10/2010
Director/Board Member 72 29/03/2016
Date Insider Type Main position Quantity % Market Cap.
28/11/25 Free

Chief Operating Officer

199,909 0.0537%
28/11/25 Free

Chief Operating Officer

287,530 0.0773%
28/11/25 Free

Chairman

744,922 0.2003%
Change 5-day change 1-year change 3-year change Capi.($)
-0.36%+4.48%-22.44%+202.70% 742M
-0.73%+7.82%+73.81%+102.34% 70.1B
-0.71%+0.16%+37.07%+65.17% 54.93B
-2.03%-2.61%+5.06%+478.86% 28.89B
+0.04%+10.49%+48.44%+7.45% 23.9B
-0.49%+1.33%-18.07%-14.00% 23.3B
-1.37%+7.87%+251.71%+464.53% 18.41B
-0.81%+7.25%+40.03%-20.59% 18.77B
-0.57%+3.44%+25.60%+619.86% 16.1B
+0.76%-4.14%+30.01%+132.64% 12.48B
Average -0.65%+7.95%+47.12%+203.90% 26.76B
Weighted average by Cap. -0.76%+9.41%+53.24%+165.86%

Financials

2026 *2027 *
Net sales - 933K 660K 572K 536K 489K 919K 62.98M 6.3M 2.46M 31.54M 2.48M 2.43M 105M
Net income -108M -76.38M -66.17M -62M -56.55M -106M -7.28B -729M -285M -3.65B -287M -281M -12.16B -121M -85.56M -74.13M -69.45M -63.35M -119M -8.16B -817M -319M -4.09B -321M -314M -13.62B
Net Debt -161M -114M -98.69M -92.47M -84.34M -159M -10.86B -1.09B -425M -5.44B -428M -418M -18.14B -49.5M -35.02M -30.34M -28.43M -25.93M -48.75M -3.34B -334M -131M -1.67B -131M -129M -5.58B
Logo Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing targeted copper theranostics based on its SAR Technology Platform. It is progressing clinical trials with its approximately three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. Its lead product, SAR-bisPSMA, is progressing through over three clinical trials: one theranostic trial (SECuRE) and two Phase III diagnostic trials (CLARIFY and AMPLIFY). SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2). SAR-bisPSMA is developed for diagnosing, staging, and treating prostate cancer that expresses prostate-specific membrane antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer.
Employees
-
Date Price Change Volume
13/08/26 A$2.800 -0.36% 1,340,798
12/08/26 A$2.810 -1.75% 1,513,138
11/08/26 A$2.860 +0.70% 1,823,533
10/08/26 A$2.840 +5.58% 3,976,187
07/08/26 A$2.690 +0.37% 2,280,036
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.810AUD
Average target price
7.202AUD
Spread / Average Target
+156.32%

Annual profits - Rate of surprise